Join the Eylea group to help and get support from people like you.
Eylea News
Monthly News Roundup - May 2024
FDA Clears GSK’s Benlysta Autoinjector for Systemic Lupus Erythematosus (SLE) in Children In May, the U.S Food and Drug Administration (FDA) cleared GSK’s Benlysta subcutaneous autoinjector (given as ...
Monthly News Roundup - May 2024
FDA Clears GSK’s Benlysta Autoinjector for Systemic Lupus Erythematosus (SLE) in Children In May, the U.S Food and Drug Administration (FDA) cleared GSK’s Benlysta subcutaneous autoinjector (given as ...
FDA Approves Yesafili (aflibercept-jbvf), an Interchangeable Biosimilar to Eylea
May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...
FDA Approves Opuviz (aflibercept-yszy), an Interchangeable Biosimilar to Eylea
May 20, 2024 – The U.S. Food and Drug Administration (FDA) has approved Opuviz (aflibercept-yszy), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products work by inhibiting...
FDA Approves Eylea HD (aflibercept) Injection 8 mg for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea HD (aflibercept)...
Eylea (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
ROP is a leading cause of childhood blindness worldwide Eylea now approved to treat five retinal conditions caused by ocular angiogenesis TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) --...
FDA Approves Eylea (aflibercept) Injection Prefilled Syringe
TARRYTOWN, N.Y., Aug. 13, 2019 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Chemistry,...
FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy
TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection to treat all...
FDA Approves New Eylea (aflibercept) Injection Dosing Schedule in Wet Age-Related Macular Degeneration
TARRYTOWN, N.Y., Aug. 17, 2018 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ : REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics...
FDA Approves Eylea (aflibercept) for Diabetic Retinopathy in Patients with Diabetic Macular Edema
March 25, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema. ...
Eylea (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema
TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept)...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Macular Degeneration, Diabetic Macular Edema